|1.||Schmiegelow, Kjeld: 15 articles (05/2015 - 04/2003)|
|2.||Relling, Mary V: 13 articles (06/2015 - 01/2002)|
|3.||Sandborn, William J: 13 articles (07/2014 - 01/2002)|
|4.||Evans, William E: 12 articles (06/2015 - 01/2002)|
|5.||Korelitz, Burton I: 12 articles (08/2014 - 04/2003)|
|6.||Gisbert, Javier P: 9 articles (05/2015 - 06/2003)|
|7.||Pui, Ching-Hon: 8 articles (04/2015 - 01/2002)|
|8.||Hanauer, Stephen B: 8 articles (11/2012 - 12/2002)|
|9.||Sparrow, Miles P: 8 articles (06/2011 - 02/2007)|
|10.||de Boer, Nanne K H: 7 articles (12/2015 - 04/2005)|
|1.||Crohn Disease (Crohn's Disease)
01/01/1999 - "AZA and its metabolite 6-mercaptopurine (6-MP) are effective in the treatment of active Crohn's disease. "
10/01/2000 - "6-Mercaptopurine in maintaining remission in Crohn's disease: An old friend becomes a new hero."
10/01/2013 - "A small placebo-controlled trial reported the efficacy of mercaptopurine therapy for children newly diagnosed with Crohn's disease, yet little is known about the efficacy of early thiopurine therapy in adults. "
08/01/2012 - "To evaluate the efficacy of elemental diet versus 6-mercaptopurine as maintenance therapy in Crohn's disease. "
07/01/1997 - "To date, none of the five patients who were placed on 6-mercaptopurine have had recurrence of their Crohn's disease (mean disease-free period 32.6 +/- 18.4 months). "
|2.||Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
04/01/2003 - "6-Mercaptopurine (6-MP) has proven efficacy in the therapy of inflammatory bowel disease. "
10/01/1989 - "Improved treatment of individuals with severe inflammatory bowel disease with potent immunosuppressive medications such as 6-mercaptopurine has been previously demonstrated. "
11/01/2010 - "6-mercaptopurine (6-MP) is used for the induction and maintenance of remission of inflammatory bowel disease (IBD). "
11/01/1995 - "[Efficacy of 6-mercaptopurine in the treatment of inflammatory bowel disease]."
10/15/1989 - "Our data, showing a low incidence of toxicity in 396 patients, coupled with the previously demonstrated efficacy of 6-mercaptopurine in the treatment of inflammatory bowel disease, indicate that the drug is a reasonable alternative in the management of patients with intractable inflammatory bowel disease."
03/01/2004 - "6-mercaptopurine has proven to be effective in the treatment and maintenance of remission of ulcerative colitis (UC). "
06/01/1990 - "The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis."
05/01/2011 - "The paper under evaluation brings new insight into the molecular events underlying EMN development in a patient receiving 6-mercaptopurine immunosuppressive therapy for ulcerative colitis. "
08/01/2010 - "6-Mercaptopurine (6-MP) is an effective maintenance medication in patients with ulcerative colitis (UC), but toxic effects like myelosuppression limit its clinical benefit. "
03/01/2008 - "We report a case of a 50-year-old woman with refractory ulcerative colitis chronically treated with 6-mercaptopurine that developed severe squamous dysplasia of the rectum. "
|4.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/01/2000 - "6-mercaptopurine (6-MP) has been used clinically for 40 years to maintain remission in patients with acute lymphoblastic leukemia (ALL). "
01/01/1991 - "To evaluate the reasons for the wide variability in bioavailability of orally administered 6-mercaptopurine in children with acute lymphoblastic leukemia, we studied several pharmacokinetic parameters of the drug in 18 affected children receiving remission maintenance therapy, and compared them with their anthropometric data and with the results of intestinal function tests. "
11/01/1989 - "Plasma levels of 6-mercaptopurine were determined in 22 consecutive children with acute lymphoblastic leukemia on oral remission maintenance therapy during the time period of August 1984 to January 1988. "
01/01/1988 - "In three children receiving oral remission maintenance therapy for acute lymphoblastic leukemia, the concentrations of 6-mercaptopurine (6-MP) in cerebrospinal fluid (CSF), plasma and red blood cells were compared. "
08/01/2004 - "A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group)."
01/01/1988 - "In earlier studies, children given DON orally in combination with 6-mercaptopurine had significant prolongation of remission of acute leukemias during maintenance therapy. "
05/01/2014 - "Among Tpmt+/+ recipient mice, leukemia-free survival improved with higher doses of mercaptopurine (similar to doses tolerated by wild-type patients) compared with lower doses, and at higher doses was comparable (P=0.6) to the survival of Tpmt-/- mice treated with the lower dose. "
08/01/1991 - "To determine whether the pharmacokinetics of 6-mercaptopurine (6-MP) would show dose dependency, we studied three different single oral doses in eight children (aged 3.6 to 15.1 years) with acute leukemia in remission. "
01/01/1992 - "A phase II trial of continuous-infusion 6-mercaptopurine for childhood leukemia."
01/01/1976 - "[Cytogenetic study of acute leukemia and the influence of 6-mercaptopurine on the chromosomes of the blood cells]."
|2.||Drug Therapy (Chemotherapy)
|5.||Combination Drug Therapy (Combination Chemotherapy)